Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MX1

Gene summary for MX1

Gene summary.

Gene information	Species	Human
	Gene symbol	MX1
	Gene ID	4599
	Gene name	MX dynamin like GTPase 1
	Gene Alias	IFI-78K
	Cytomap	21q22.3
	Gene Type	protein-coding
	GO ID	GO:0002376
	UniProtAcc	P20591

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4599	MX1	GSM4909281	Human	Breast	IDC	5.11e-05	2.73e-01	0.21
4599	MX1	GSM4909285	Human	Breast	IDC	3.92e-16	5.56e-01	0.21
4599	MX1	GSM4909287	Human	Breast	IDC	4.92e-17	4.84e-01	0.2057
4599	MX1	GSM4909305	Human	Breast	IDC	4.92e-04	1.69e-01	0.0436
4599	MX1	GSM4909307	Human	Breast	IDC	1.48e-05	3.15e-01	0.1569
4599	MX1	GSM4909308	Human	Breast	IDC	3.46e-17	3.56e-01	0.158
4599	MX1	GSM4909309	Human	Breast	IDC	3.59e-09	3.09e-01	0.0483
4599	MX1	GSM4909317	Human	Breast	IDC	1.84e-03	1.39e-01	0.1355
4599	MX1	GSM4909321	Human	Breast	IDC	9.44e-10	4.75e-01	0.1559
4599	MX1	M1	Human	Breast	IDC	2.72e-11	3.40e-01	0.1577
4599	MX1	NCCBC5	Human	Breast	DCIS	8.58e-30	9.46e-01	0.2046
4599	MX1	P1	Human	Breast	IDC	2.74e-06	4.03e-01	0.1527
4599	MX1	P2	Human	Breast	IDC	3.09e-24	8.05e-01	0.21
4599	MX1	DCIS2	Human	Breast	DCIS	8.45e-25	2.72e-01	0.0085
4599	MX1	CA_HPV_1	Human	Cervix	CC	6.52e-22	7.42e-01	0.0264
4599	MX1	CA_HPV_2	Human	Cervix	CC	4.43e-18	6.52e-01	0.0391
4599	MX1	HSIL_HPV_1	Human	Cervix	HSIL_HPV	3.44e-02	-2.79e-02	0.0116
4599	MX1	CCI_2	Human	Cervix	CC	1.26e-09	1.01e+00	0.5249
4599	MX1	CCI_3	Human	Cervix	CC	8.72e-03	5.29e-01	0.516
4599	MX1	Tumor	Human	Cervix	CC	2.93e-23	6.01e-01	0.1241

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603214	Breast	IDC	viral process	75/1434	415/18723	1.98e-12	4.02e-10	75
GO:001905814	Breast	IDC	viral life cycle	61/1434	317/18723	1.61e-11	2.77e-09	61
GO:001907914	Breast	IDC	viral genome replication	32/1434	131/18723	2.82e-09	2.46e-07	32
GO:005079214	Breast	IDC	regulation of viral process	36/1434	164/18723	6.55e-09	5.03e-07	36
GO:190390014	Breast	IDC	regulation of viral life cycle	30/1434	148/18723	7.25e-07	3.35e-05	30
GO:004506913	Breast	IDC	regulation of viral genome replication	20/1434	85/18723	4.77e-06	1.63e-04	20
GO:00096157	Breast	IDC	response to virus	47/1434	367/18723	3.53e-04	5.16e-03	47
GO:004852512	Breast	IDC	negative regulation of viral process	17/1434	92/18723	5.58e-04	7.10e-03	17
GO:00450713	Breast	IDC	negative regulation of viral genome replication	11/1434	56/18723	3.08e-03	2.61e-02	11
GO:001603224	Breast	DCIS	viral process	73/1390	415/18723	3.40e-12	6.88e-10	73
GO:001905824	Breast	DCIS	viral life cycle	59/1390	317/18723	4.05e-11	5.74e-09	59
GO:001907923	Breast	DCIS	viral genome replication	30/1390	131/18723	2.12e-08	1.45e-06	30
GO:005079222	Breast	DCIS	regulation of viral process	34/1390	164/18723	3.58e-08	2.30e-06	34
GO:190390022	Breast	DCIS	regulation of viral life cycle	28/1390	148/18723	3.79e-06	1.16e-04	28
GO:004506923	Breast	DCIS	regulation of viral genome replication	18/1390	85/18723	4.23e-05	8.98e-04	18
GO:000961512	Breast	DCIS	response to virus	45/1390	367/18723	6.16e-04	7.82e-03	45
GO:004852521	Breast	DCIS	negative regulation of viral process	15/1390	92/18723	3.07e-03	2.61e-02	15
GO:001603210	Cervix	CC	viral process	109/2311	415/18723	5.40e-15	6.46e-12	109
GO:001905810	Cervix	CC	viral life cycle	87/2311	317/18723	2.20e-13	1.20e-10	87
GO:001907910	Cervix	CC	viral genome replication	35/2311	131/18723	6.11e-06	1.49e-04	35

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0517124	Breast	IDC	Coronavirus disease - COVID-19	86/867	232/8465	1.50e-28	9.72e-27	7.27e-27	86
hsa0517134	Breast	IDC	Coronavirus disease - COVID-19	86/867	232/8465	1.50e-28	9.72e-27	7.27e-27	86
hsa0517144	Breast	DCIS	Coronavirus disease - COVID-19	86/846	232/8465	2.42e-29	1.56e-27	1.15e-27	86
hsa0517154	Breast	DCIS	Coronavirus disease - COVID-19	86/846	232/8465	2.42e-29	1.56e-27	1.15e-27	86
hsa0517120	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa051657	Cervix	CC	Human papillomavirus infection	74/1267	331/8465	1.70e-04	1.02e-03	6.03e-04	74
hsa0516414	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa05171110	Cervix	CC	Coronavirus disease - COVID-19	111/1267	232/8465	1.82e-33	5.90e-31	3.49e-31	111
hsa0516512	Cervix	CC	Human papillomavirus infection	74/1267	331/8465	1.70e-04	1.02e-03	6.03e-04	74
hsa0516415	Cervix	CC	Influenza A	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa0517125	Cervix	HSIL_HPV	Coronavirus disease - COVID-19	91/459	232/8465	2.14e-56	3.13e-54	2.53e-54	91
hsa0516422	Cervix	HSIL_HPV	Influenza A	23/459	171/8465	4.65e-05	6.48e-04	5.24e-04	23
hsa0517135	Cervix	HSIL_HPV	Coronavirus disease - COVID-19	91/459	232/8465	2.14e-56	3.13e-54	2.53e-54	91
hsa0516432	Cervix	HSIL_HPV	Influenza A	23/459	171/8465	4.65e-05	6.48e-04	5.24e-04	23
hsa051714	Colorectum	MSS	Coronavirus disease - COVID-19	108/1875	232/8465	6.50e-17	1.67e-15	1.03e-15	108
hsa051602	Colorectum	MSS	Hepatitis C	52/1875	157/8465	9.29e-04	5.58e-03	3.42e-03	52
hsa03250	Colorectum	MSS	Viral life cycle - HIV-1	23/1875	63/8465	6.55e-03	2.64e-02	1.62e-02	23
hsa051715	Colorectum	MSS	Coronavirus disease - COVID-19	108/1875	232/8465	6.50e-17	1.67e-15	1.03e-15	108
hsa051603	Colorectum	MSS	Hepatitis C	52/1875	157/8465	9.29e-04	5.58e-03	3.42e-03	52
hsa032501	Colorectum	MSS	Viral life cycle - HIV-1	23/1875	63/8465	6.55e-03	2.64e-02	1.62e-02	23

Page: 1 2 3 4 5 6

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MX1

SNV

Missense_Mutation

rs375569357

c.401N>T

p.Ser134Leu

p.S134L

P20591

protein_coding

tolerated(0.17)

benign(0.005)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MX1

SNV

Missense_Mutation

novel

c.1502C>A

p.Thr501Asn

p.T501N

P20591

protein_coding

deleterious(0.02)

benign(0.393)

TCGA-AN-A0FX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

MX1

SNV

Missense_Mutation

novel

c.1864N>C

p.Asp622His

p.D622H

P20591

protein_coding

deleterious(0)

probably_damaging(0.965)

TCGA-B6-A0I1-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MX1

SNV

Missense_Mutation

novel

c.1435A>G

p.Met479Val

p.M479V

P20591

protein_coding

tolerated(0.1)

benign(0.156)

TCGA-BH-A0DO-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MX1

SNV

Missense_Mutation

c.262N>C

p.Glu88Gln

p.E88Q

P20591

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-C8-A12Z-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

MX1

SNV

Missense_Mutation

novel

c.1722N>A

p.Met574Ile

p.M574I

P20591

protein_coding

tolerated(0.97)

benign(0.003)

TCGA-HN-A2NL-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

MX1

insertion

In_Frame_Ins

novel

c.495_496insGACCTGGTGAATTGGACACTCTGGGGC

p.Glu165_Ile166insAspLeuValAsnTrpThrLeuTrpGly

p.E165_I166insDLVNWTLWG

P20591

protein_coding

TCGA-A8-A09D-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

MX1

insertion

Frame_Shift_Ins

novel

c.190_191insC

p.Val64AlafsTer56

p.V64Afs*56

P20591

protein_coding

TCGA-BH-A0AY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

MX1

insertion

Frame_Shift_Ins

novel

c.191_192insACCTAGTGAGTGCCTCCATTTTGAGACATTAG

p.Glu65ProfsTer49

p.E65Pfs*49

P20591

protein_coding

TCGA-BH-A0AY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

MX1

SNV

Missense_Mutation

c.700G>C

p.Glu234Gln

p.E234Q

P20591

protein_coding

tolerated(0.07)

possibly_damaging(0.718)

TCGA-C5-A1BI-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1